Newer drug-eluting stents reduce restenosis by 38%, thrombosis by half

Newer is better when it comes to drug-eluting stents, according to a report from the Swedish Coronary Angiography and Angioplasty Registry. Newer models are associated with a 38% lower risk of restenosis and a 50% lower risk of stent thrombosis compared with old-school drug-eluting stents. Among the reasons are improved stent designs with thinner struts and more biocompatible polymers that may have an important impact on drug elution, the group says.

Using a national registry, the study evaluated the long-term outcome in all patients who underwent stent implantation with bare-metal stents, "older generation" drug-eluting stents, and "new generation" drug-eluting stents in Sweden.

The group says more studies are needed to determine what component of the new drug-eluting stents is involved in the decrease in thrombosis or restenosis--the polymer, the stent alloy or the eluting-drug.

- read the release from the European Society of Cardiology

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.